- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Apellis Pharmaceuticals Inc (APLS)
41.03
-0.03(-0.07%)
Closed·
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
41.03
41.07
52 wk Range
16.61
41.14
APLS Comments
Compiled here, all relevant comments and discussions regarding the APLS stock. Please note that all comments included here have met Investing.com's Comment Guidelines.
though the ruff
The FDA has approved Apellis' EMPAVELI (pegcetacoplan) as the first treatment for *C3 glomerulopathy (C3G) and primary immune complex membranoproliferative glomerulonephritis (IC-MPGN)* in patients aged 12 and older. This approval was announced on *July 28, 2025*. *Key Highlights of the Approval:* - *Efficacy*: EMPAVELI showed a *68% reduction in proteinuria*, stabilized kidney function, and substantial clearance of C3 deposits. - *Label*: Covers adults and adolescents with C3G or primary IC-MPGN, including post-transplant C3G disease recurrence. - *Safety*: A well-established safety profile across over *2,200 patient years* in approved indications. - *Conference Call*: Scheduled for tomorrow at 8:00 a.m. ET to discuss the approval. C3G and primary IC-MPGN are rare kidney diseases with a high risk of progressing to kidney failure. EMPAVELI is now a treatment option for these conditions
Day's Range: 45.75 - 51.00
and maybe more green candles arrive
in max 3 month APLS will be above 50USD, pls see the main big investors list , and take actions in consequences :)
Selling 1/3 of position
big potential here, easy 50% can be made
Yeah, but it just keeps going down every day.
Buying it
7 people has some retina damaged probably this news impact the stock. Check news
7 on over 60.000…
60000 people or pieces of shrinkage pieces..
What is wrong with this stock?? The earnings are great, the news are great, but it deep 14%
Tell me about it...
Maybe manipulation from market-makers
will go up today maybe to 30
Buy it, short squeeze in few days
it's time to buy cheap.
are you sure, don't you think it will lose more value?
I think the best time for buy it's October November. they lose more value all summer
This is the kind of stocks you normally don't have the chance to buy cheap. One thing semi-wrong and it tumbled 40%. But, it doesn't justify today's price. This will skyrocket also with one good thing. One huge investor just left the company but also left cheap price stock.
CCXI...FDA approval July 7th. This stock will skyrocket from cancer treatment drug!! Yw 🤑CCXI...FDA approval July 7th. This stock will skyrocket from cancer treatment drug!! Yw 🤑
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.